Credit Suisse’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-73,902
| Closed | -$1.49M | – | 4746 |
|
|
2021
Q3 | $1.49M | Sell |
73,902
-14,440
| -16% | -$399K | ﹤0.01% | 3040 |
|
|
2021
Q2 | $3.29M | Buy |
88,342
+12,757
| +17% | +$391K | ﹤0.01% | 2447 |
|
|
2021
Q1 | $1.93M | Sell |
75,585
-32,843
| -30% | -$839K | ﹤0.01% | 2846 |
|
|
2020
Q4 | $2.39M | Buy |
108,428
+3,936
| +4% | +$86.7K | ﹤0.01% | 2687 |
|
|
2020
Q3 | $1.88M | Sell |
104,492
-6,373
| -6% | -$132K | ﹤0.01% | 2465 |
|
|
2020
Q2 | $2.82M | Buy |
110,865
+82,262
| +288% | +$1.77M | ﹤0.01% | 2113 |
|
|
2020
Q1 | $525K | Sell |
28,603
-44,570
| -61% | -$866K | ﹤0.01% | 3077 |
|
|
2019
Q4 | $1.61M | Buy |
73,173
+44,506
| +155% | +$896K | ﹤0.01% | 2791 |
|
|
2019
Q3 | $412K | Sell |
28,667
-9,373
| -25% | -$134K | ﹤0.01% | 3538 |
|
|
2019
Q2 | $600K | Sell |
38,040
-6,554
| -15% | -$89.1K | ﹤0.01% | 3294 |
|
|
2019
Q1 | $653K | Buy |
44,594
+16,574
| +59% | +$190K | ﹤0.01% | 3194 |
|
|
2018
Q4 | $299K | Buy |
28,020
+11,925
| +74% | +$157K | ﹤0.01% | 3519 |
|
|
2018
Q3 | $245K | Sell |
16,095
-4,126
| -20% | -$60.1K | ﹤0.01% | 3595 |
|
|
2018
Q2 | $247K | Buy |
+20,221
| New | +$254K | ﹤0.01% | 3694 |
|
|
2016
Q4 | – | Sell |
-10,245
| Closed | -$60K | – | 4286 |
|
|
2016
Q3 | $60K | Sell |
10,245
-43,867
| -81% | -$154K | ﹤0.01% | 4000 |
|
|
2016
Q2 | $163K | Buy |
+54,112
| New | +$222K | ﹤0.01% | 3941 |
|
|
2016
Q1 | – | Sell |
-15,886
| Closed | -$189K | – | 4384 |
|
|
2015
Q4 | $189K | Buy |
+15,886
| New | +$182K | ﹤0.01% | 3914 |
|
|
2015
Q3 | – | Sell |
-12,833
| Closed | -$179K | – | 4564 |
|
|
2015
Q2 | $179K | Buy |
+12,833
| New | +$235K | ﹤0.01% | 4263 |
|
|
2014
Q4 | – | Sell |
-12,536
| Closed | -$159K | – | 4789 |
|
|
2014
Q3 | $159K | Buy |
+12,536
| New | +$189K | ﹤0.01% | 4211 |
|
Other funds holding DRNA
Credit Suisse's DRNA Position: Q4 2021 in Review
Credit Suisse sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 73,902 shares — an estimated $1.49M sold.
Credit Suisse first reported a position in DRNA in Q3 2014 and held it in 19 quarters. The position peaked at $3.29M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Credit Suisse reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Credit Suisse sold 73,902 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.49M.
- Credit Suisse first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2014 and held it in 19 quarters.
- Credit Suisse's Dicerna Pharmaceuticals, Inc. position peaked at $3.29M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Credit Suisse's 13F filing for Q4 2021, filed 14 Feb 2022.